Search Results - "Jeanfreau, Robert"

Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial by Essink, Brandon J., Heeringa, Marten, Jeanfreau, Robert J., Finn, Daniel, Matassa, Vince, Edelman, Jonathan, Hohenboken, Matthew, Molrine, Deborah

“…OBJECTIVE Young children are at increased risk for influenza-related complications. Safety and immunogenicity of a cell-based quadrivalent inactivated…”
Get full text

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study by Esteves-Jaramillo, Alejandra, Koehler, Timothy, Jeanfreau, Robert, Neveu, David, Jordanov, Emilia, Singh Dhingra, Mandeep

“…•No meningococcal polysaccharide vaccines are licensed for ≥56-year-olds in the USA.•MenACYW-TT is a quadrivalent polysaccharide tetanus toxoid conjugate…”
Get full text

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study by Áñez, Germán, Hedrick, James, Simon, Michael W., Christensen, Shane, Jeanfreau, Robert, Yau, Eddy, Pan, Judy, Jordanov, Emilia, Dhingra, Mandeep S.

“…The quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) was assessed as a booster in this Phase III trial (NCT02752906). Quadrivalent…”
Get full text

A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly Adults by Talaat, Kawsar R., Greenberg, Michael E., Lai, Michael H., Hartel, Gunter F., Wichems, Christine H., Rockman, Steven, Jeanfreau, Robert J., Rita Ghosh, M., Kabongo, Martin L., Gittleson, Charmaine, Karron, Ruth A.

“…Background. When the novel H1N1 influenza A strain appeared in April of 2009, development of novel H1N1 vaccines became a public health priority. Methods. We…”
Get full text

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

“…The titer of live attenuated viral vaccines, such as MMR vaccines, varies between batches and over the shelf-life of a batch, with the highest titer expected…”
Get full text

Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial by de Bruyn, Guy, Gordon, David L, Steiner, Theodore, Tambyah, Paul, Cosgrove, Catherine, Martens, Mark, Bassily, Ehab, Chan, Eng-Soon, Patel, Dhaval, Chen, Josh, Torre-Cisneros, Julian, Fernando De Magalhães Francesconi, Carlos, Gesser, Richard, Jeanfreau, Robert, Launay, Odile, Laot, Thelma, Morfin-Otero, Rayo, Oviedo-Orta, Ernesto, Park, Yoon Soo, Piazza, Franco M, Rehm, Christine, Rivas, Enrique, Self, Steve, Gurunathan, Sanjay

“…In the absence of a licensed vaccine, Clostridioides (formerly Clostridium) difficile infection represents a substantial health burden. The aim of this study…”
Get full text

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial by Bebia, Zourab, Reyes, Osvaldo, Jeanfreau, Robert, Kantele, Anu, De Leon, Ruth Graciela, Sánchez, Marta García, Banooni, Peyman, Gardener, Glenn J, Rasero, José Luis Bartha, Pardilla, Maria Begoña Encinas, Langley, Joanne M, Di Leo, Claudio Maañón, Botelho-Nevers, Elisabeth, Buttery, Jim, Laurichesse, Helene, Madhi, Shabir A, García, Adrián Martín, Stanley, Thorsten, Barjat, Tiphaine, Griffith, Rebecca, Castrejón-Alba, Maria Mercedes, de Heusch, Magali, Dieussaert, Ilse, Hercor, Melanie, Lese, Patricia, Qian, Hui, Tullio, Antonella N, Henry, Ouzama

“…Abstract Background In a phase 1/2 study, a maternal respiratory syncytial virus vaccine candidate (RSVPreF3) demonstrated an acceptable safety profile and…”
Get full text

Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial by Criner, Gerard J, Lang, Frederick M, Gottlieb, Robert L, Mathews, Kusum S, Wang, Tisha S, Rice, Todd W, Madduri, Deepu, Bellam, Shashi, Jeanfreau, Robert, Case, Amy H, Glassberg, Marilyn K, Lyon, George Marshall, Ahmad, Kareem, Mendelson, Robert, DiMaio, J Michael, Tran, MaryAnn P, Spak, Cedric W, Abbasi, Jamil A, Davis, Steven G, Ghamande, Shekhar, Shen, Steven, Sherman, Lisa, Lowry, Simon

“…GM-CSF (granulocyte-macrophage colony-stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with…”
Get full text

Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial by Robertson, Corwin A, Mercer, Monica, Selmani, Alexandre, Klein, Nicola P, Jeanfreau, Robert, Greenberg, David P

“…BACKGROUND:For children <3 years of age, a half dose of inactivated influenza vaccine (7.5 μg hemagglutinin per strain) has been used for more than 30 years,…”
Get full text

Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial by Dixit, Avika, Bennett, Richard, Ali, Kashif, Griffin, Carl, Clifford, Robert A, Turner, Mark, Poston, Rosanne, Hautzinger, Kelly, Yeakey, Anne, Girard, Bethany, Zhou, Wen, Deng, Weiping, Zhou, Honghong, Schnyder Ghamloush, Sabine, Kuter, Barbara J, Slobod, Karen, Miller, Jacqueline M, Priddy, Frances, Das, Rituparna, Ali, Kashif, Ampajwala, Madhavi, Atz, Andrew, Bennett, Richard, Berman, Gary, Clifford, Robert, Dunn, Michael, Eder, Frank, Fuchs, George, Griffin, Carl, Hernandez, John M., Jeanfreau, Robert, Johnson, Kimball, Lavery, William, Meyer, Jay, Muller, William, Ohnmacht, Richard, Padhye, Amruta, Palanpurwala, Khozema, Rodrigue, Carina, Turner, Mark, Vasko, Todd, Waits, John, Warfield, Peter

“…Variant-containing mRNA vaccines for COVID-19 to broaden protection against SARS-CoV-2 variants are recommended based on findings in adults. We report interim…”
Get full text

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial by Chang, Lee-Jah, Anderson, Evan J., Jeanfreau, Robert, He, Ying, Hicks, Bryony, Shrestha, Anju, Pandey, Aseem, Landolfi, Victoria, DeBruijn, Iris

“…•Safety and immunogenicity of IIV4-HD was evaluated in USA and Canadian children 6 mos.-17 yrs. of age.•Three dose formulations of IIV4-HD (30 45, and 60 µg…”
Get full text

Generation of recombinant hyperimmune globulins from diverse B-cell repertoires by Keating, Sheila M., Mizrahi, Rena A., Adams, Matthew S., Asensio, Michael A., Benzie, Emily, Carter, Kyle P., Chiang, Yao, Edgar, Robert C., Gautam, Bishal K., Gras, Ashley, Leong, Jackson, Leong, Renee, Lim, Yoong Wearn, Manickam, Vishal A., Medina-Cucurella, Angelica V., Niedecken, Ariel R., Saini, Jasmeen, Simons, Jan Fredrik, Spindler, Matthew J., Stadtmiller, Kacy, Tinsley, Brendan, Wagner, Ellen K., Wayham, Nicholas, Tracy, LaRee, Lundberg, Carina Vingsbo, Büscher, Dirk, Terencio, Jose Vicente, Roalfe, Lucy, Pearce, Emma, Richardson, Hayley, Goldblatt, David, Ramjag, Anushka T., Carrington, Christine V. F., Simmons, Graham, Muench, Marcus O., Chamow, Steven M., Monroe, Bryan, Olson, Charles, Oguin, Thomas H., Lynch, Heather, Jeanfreau, Robert, Mosher, Rachel A., Walch, Matthew J., Bartley, Christopher R., Ross, Carl A., Meyer, Everett H., Adler, Adam S., Johnson, David S.

“…Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient…”
Get full text

AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial by Kosalaraksa, Pope, Jeanfreau, Robert, Frenette, Louise, Drame, Mamadou, Madariaga, Miguel, Innis, Bruce L., Godeaux, Olivier, Izurieta, Patricia, Vaughn, David W.

“…Background. This phase 2/3, randomized, placebo-controlled, observer-blinded study assessed the immunogenicity, reactogenicity, and safety of an inactivated,…”
Get full text

AS03 sub(B)-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial by Kosalaraksa, Pope, Jeanfreau, Robert, Frenette, Louise, Drame, Mamadou, Madariaga, Miguel, Innis, Bruce L, Godeaux, Olivier, Izurieta, Patricia, Vaughn, David W

“…Background. This phase 2/3, randomized, placebo-controlled, observer-blinded study assessed the immunogenicity, reactogenicity, and safety of an inactivated,…”
Get full text

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age by Halperin, Scott A, Gupta, Anil, Jeanfreau, Robert, Klein, Nicola P, Reisinger, Keith, Walter, Emmanuel, Bedell, Lisa, Gill, Christopher, Dull, Peter M

“…Abstract Background Routine administration of quadrivalent meningococcal conjugate vaccine to adolescents and certain high risk groups is recommended in the…”
Get full text

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial by Langley, Joanne M, Frenette, Louise, Jeanfreau, Robert, Halperin, Scott A, Kyle, Michael, Chu, Laurence, McNeil, Shelly, Dramé, Mamadou, Moris, Philippe, Fries, Louis, Vaughn, David W

“…Highlights • We compared an AS03-adjuvanted H5N1 vaccine at different dose levels to placebo. • We compared the effect of a vaccine boost 6 or 18 months later…”
Get full text

160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age by Chang, Leejah, Anderson, Evan J, Jeanfreau, Robert, He, Ying, Hicks, Bryony, Shrestha, Anju, Pandey, Aseem, Khoury, Rawia, De Bruijn, Iris, Landolfi, Victoria

“…Abstract Background Children do not respond immunologically as well as adults to standard-dose (SD) influenza vaccination and remain at increased risk of…”
Get full text

2462. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Individuals 56 Years of Age and Older by Jeanfreau, Robert, Esteves-Jaramillo, Alejandra, Neveu, David, Jordanov, Emilia, Dhingra, Mandeep S

Get full text

4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results from a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults by Nolan, Terry, Bhusal, Chiranjiwi, Beran, Jiří, Bloch, Mark, Cetin, Benhur S, Dinleyici, Ener C, Dražan, Daniel, Kokko, Satu, Koski, Susanna, Laajalahti, Outi, Langley, Joanne M, Rämet, Mika, Richmond, Peter C, Silas, Peter, Tapiero, Bruce, Tiong, Florence, Tipton, Mary, Ukkonen, Benita, Ulukol, Betul, Lattanzi, Maria, Trapani, Mauro, Willemsen, Arnold, Toneatto, Daniela, Ackerman, Ronald, Adamovska, Renata, Athan, Eugene, Ayesu, Kwabena, Beran, Jiří, Bernard, David, Bhusal, Chiranjiwi, Bloch, Mark, Byars, William, Carter, Robert, Cetin, Benhur, Chakerian, Maia, Dalebout, Marije, de Looze, Ferdinandus, Dinleyici, Ener Cagri, Dionne, Marc, Dražan, Daniel, Dzongowski, Peter, Farjo, Rand, Finn, Daniel, Freeman, George, Gottfredson, Ryan, Grubb, Paul, Gupta, Anil, Ince, Tolga, Jeanfreau, Robert, Jones, Jake, Kellner, James, Kiiroja, Kaia, Kokko, Satu, Koski, Susanna, Langley, Joanne, Laajalahti, Outi, Lattanzi, Maria, Lechevin, Isabelle, Mehta, Hemalini, Meisalu, Sandra, Morelle, Danielle, Nolan, Terry, Osowa, Alexander, Paavola, Pauliina, Patel, Minesh, Pavlasek, Miroslav, Pelayo, Enrique, Rämet, Mika, Raulier, Stefanie, Richmond, Peter, Rok, Walter, Rouhbakhsh, Rambod, Sadarangani, Manish, Sanchez, Yamirka, Schear, Martin, Scott, John, Seppä, Ilkka, Silas, Peter, Simon, William, Spaziererova, Martina, Staben, Jonathan, Surber, Joseph, Tapiero, Bruce, Tiong, Florence, Tipton, Mary, Toneatto, Daniela, Trapani, Mauro, Ukkonen, Benita, Ulukol, Betul, Vachon, Marie-Louise, Vale, Noah, Wauters, Dominique, Willemsen, Arnold, Zemanek, Josef

“…Abstract Background Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2,…”
Get full text

Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial by Jain, Varsha K, Domachowske, Joseph B, Wang, Long, Ofori-Anyinam, Opokua, Rodríguez-Weber, Miguel A, Leonardi, Michael L, Klein, Nicola P, Schlichter, Gary, Jeanfreau, Robert, Haney, Byron L, Chu, Laurence, Harris, Jo-Ann S, Sarpong, Kwabena O, Micucio, Amanda C, Soni, Jyoti, Chandrasekaran, Vijayalakshmi, Li, Ping, Innis, Bruce L

“…Children under 3 years of age may benefit from a double-dose of inactivated quadrivalent influenza vaccine (IIV4) instead of the standard-dose. We compared the…”
Get full text